A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension

NCT01634295 Phase 3 COMPLETED

The aim of present study is to evaluate the efficacy and safety of two dose combination of S-Amlodipine/Telmisartan (2.5/40mg, 2.5/80mg and 5/80mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.

Details

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 3
Status	COMPLETED
Enrolment	103
Start date	2012-07
Completion	2013-05

Conditions

• Hypertension

Interventions

• CKD-828 2.5/40mg
• CKD-828 5/40mg
• CKD-828 5/80mg
• S-amlodipine 2.5mg
• S-amlodipine 5mg

Primary outcomes

• Mean Sitting systolic Blood Pressure (MSSBP) — After 10 weeks of treatment

Countries

South Korea